Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers
- 1 April 2009
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (4), 1450-1456
- https://doi.org/10.1128/aac.01027-08
Abstract
Although information about the efficacy and safety experience with caspofungin at 50 mg/m 2 daily is available for children and adolescents, the dosing regimen in infants and toddlers 3 to 24 months of age has yet to be established. We studied the pharmacokinetics and safety of caspofungin at 50 mg/m 2 once daily in nine patients 10 to 22 months (median, 13 months) of age with fever and neutropenia who received caspofungin once daily for 2 to 21 (mean, 9.3) days. Plasma caspofungin concentrations were measured by high-performance liquid chromatography assay on days 1 and 4. On day 4, the area under the curve from 0 to 24 h (AUC 0-24 ) was 130.3 μg-h/ml, the peak concentration ( C 1 ) was 17.2 μg/ml, and the trough concentration ( C 24 ) was 1.6 μg/ml. The day 4 geometric mean ratios (GMRs) and 90% confidence interval (CI) for these parameters in infants/toddlers relative to adults were 1.26 (1.06, 1.50), 1.83 (1.57, 2.14), and 0.81 (0.64, 1.04), respectively. Relative to children (2 to 11 years of age), the day 4 GMRs (and 90% CI) were 1.13 (0.89, 1.44), 1.10 (0.85, 1.42), and 1.12 (0.72, 1.76), respectively. The harmonic mean elimination phase t 1/2 in infants/toddlers (8.8 h) was reduced ∼33% relative to adults (13.0 h) but was similar to that in children (8.2 h). Clinical adverse events occurred in seven patients (78%); none were considered drug related. Laboratory adverse events occurred in five patients (56%) and were considered drug related in three (33%). There were no infusion-related events or discontinuations due to toxicity. Caspofungin at 50 mg/m 2 daily was well tolerated in infants and toddlers; the AUC and caspofungin C 24 were generally comparable to those in adults receiving caspofungin at 50 mg daily.Keywords
This publication has 23 references indexed in Scilit:
- Safety and Pharmacokinetics of Higher Doses of Caspofungin in Healthy Adult ParticipantsThe Journal of Clinical Pharmacology, 2011
- Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of AgeAntimicrobial Agents and Chemotherapy, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Caspofungin for the treatment of less common forms of invasive candidiasisJournal of Antimicrobial Chemotherapy, 2007
- Frequency of Fungemia in Hospitalized Pediatric Inpatients Over 11 Years at a Tertiary Care InstitutionPublished by American Academy of Pediatrics (AAP) ,2005
- HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGINPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2005
- Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal TherapyClinical Infectious Diseases, 2004
- Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 2004
- Response and Relapse Rates of Candidal Esophagitis in HIV-Infected Patients Treated with CaspofunginAIDS Research and Human Retroviruses, 2002
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International ConsensusClinical Infectious Diseases, 2002